This study will determine the safety and efficacy of JCAR017, a therapy that uses a patient’s own T-cells to fight cancer, in adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
The goal of this study is to determine the effect of JCAR017 and the recommended dose schedule. Phase one of this study will determine the recommended dose of JCAR017 monotherapy. The randomized Phase 2 portion will assess JCAR017 monotherapy treatment versus standard of care (SOC), with the possibility of crossover in patients on the SOC arm.
Juno Therapeutics is the sponsor of this study.